Allianz Asset Management
BDTX icon

Allianz Asset Management’s Black Diamond Therapeutics BDTX Stock Holding History

Allianz Asset Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,405
Closed -$252K – 2391
2021
Q1 		$252K Sell
10,405
-25,880
-71% -$698K ﹤0.01% 2079
2020
Q4 		$1.16M Sell
36,285
-14,688
-29% -$483K ﹤0.01% 1450
2020
Q3 		$1.54M Buy
50,973
+30,309
+147% +$922K ﹤0.01% 1329
2020
Q2 		$871K Sell
20,664
-5,033
-20% -$185K ﹤0.01% 1866
2020
Q1 		$641K Buy
+25,697
New +$782K ﹤0.01% 1961

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Allianz Asset Management's BDTX Position: Q2 2021 in Review

Allianz Asset Management sold out of Black Diamond Therapeutics (BDTX) in Q2 2021, closing a stake of 10,405 shares — an estimated $252K sold.

Allianz Asset Management first reported a position in BDTX in Q1 2020 and held it in 5 quarters. The position peaked at $1.54M in Q3 2020. 102 funds tracked by Wall St. Rank hold BDTX as of Q2 2021.

  • Allianz Asset Management reported no remaining Black Diamond Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Allianz Asset Management sold 10,405 Black Diamond Therapeutics shares in Q2 2021, an estimated $252K.
  • Allianz Asset Management first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 5 quarters.
  • Allianz Asset Management's Black Diamond Therapeutics position peaked at $1.54M in Q3 2020.
  • 102 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2021.

Based on Allianz Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.